Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement for Elesclomol in Disorders of Mitochondrial Copper Metabolism
Retrieved on:
Wednesday, September 8, 2021
Mitochondrial copper metabolism disorders, such as ultra-orphan Menkes disease, are devastating for patients and families, said Vikram Sudarsan, Ph.D., CEO and President of Engrail Therapeutics.
Key Points:
- Mitochondrial copper metabolism disorders, such as ultra-orphan Menkes disease, are devastating for patients and families, said Vikram Sudarsan, Ph.D., CEO and President of Engrail Therapeutics.
- Engrail will continue to work closely with academic institutions and industry partnerships to expand our pipeline of therapeutics for patients with significant unmet needs in the neurosciences.
- In addition, further nonclinical work will be completed through a sponsored research agreement with Texas A&M AgriLife Research.
- The Texas A&M University System is one of the largest systems of higher education in the nation, with a budget of $9.6 billion.